|
professors,
and another 3 were entitled “Peking Union Medical College Scholars”. In
the recent years, the institute has proudly employed over 30 talented
and dedicated scientists.
The fundamental task of IMM centers on research and discovery of
innovative drugs useful in treating or preventing human diseases. To
fulfill this goal, creative multidiscipline researches based on Chinese
herbal medicine and natural product research, along with adoption of
modern medical and pharmaceutical theories and technologies, are highly
encouraged. Currently, ongoing projects in this institute covers a
number of important research areas, including cancer, cardio and
cerebral vascular diseases, psycho and neuro-disorders, aging associated
regressive diseases, hepatitis, inflammatory and immuno disorders and
diabetes.
IMM comprises of seven departments: Department of Synthetic Medicinal
Chemistry, Department of Natural Medicinal Chemistry, Department of
Pharmacology, Department of Drug Analysis, Department of Biosynthesis,
Department 1 of Drug Development Research and Department 2 of Drug
Development Research. Being a full-range-disciplined research
institution, IMM’s capacity in drug research and development is well
recognized nationalwide. Its programs in natural product research,
computer aided drug design, combinatorial chemistry, molecular
pharmacology and high-through-put screening, enjoys great prestige in
China.
In addition, the institute also hosts a number of government-sponsored
special research centers, including the National Research Center for
Analysis of Drugs and Metabolites, the National Engineering Research
Center for Development of New Drugs, the National Center for
Pharmaceutical Screening, Pharmacodynamics Platform (Ministry of Science
& Technology), New Drug Safety Evaluation Center [the Chinese Academy of
Medical Sciences (CAMS) and Peking Union Medical College (PUMC)], the
Key laboratory of Biosynthesis of Natural Products (Ministry of Health),
and the Key Laboratory of Bioactive Substances and Resources Utilization
of Chinese Herbal Medicine (Ministry of Education). In 2011, it has been
approved for the establishment of the State Key Laboratory of Bioactive
Substance and Function of Natural Medicines, and three Beijing City
Key Laboratories, which is Beijing City Key Laboratory of Active
Substances discovery and Drugability Evaluation, Beijing City Key
Laboratory for Drug Target Identification and Drug Screening, as well as
Beijing City Key Laboratory of Drug Delivery Technology and Novel
Formulations. Since 2008, several major national platform programs
funded by central government have been established in IMM to further
enhance the drug R&D capacity, and it has substantially improved our
research quality.
There are also several IMM-owned enterprises manufacturing drug products
and providing technical services. They are Beijing Union Pharmaceutical
Factory, Beijing Union Second Pharmaceutical Factory, Beijing LianXin
Pharmaceutic Co., Ltd., Beijing Union-Genius Pharmaceutical Technology
Co., Ltd., Beijing Collab Pharma Co., Ltd. In general, through
combination of basic research and R&D application, IMM serves the nation
and patients with new drugs as well as industrial drug production.
Since the time of its establishment, scientists in this institute have
accomplished research for more than 100 marketed drugs and 129 new drug
certificates, including 19 Class I novel drugs. 261 government and
society awards or prizes were granted to the contributors for their
research efforts in drug R&D. Since the inception of the new research
funding system in China in 1986, over 900 IMM grant applications have
been approved in total. These studies have resulted in more than 6000
publications, 350 monographs, as well as 500 domestic and international
patent applications.
IMM is also a national core base for the training of high-quality
pharmaceutical professionals. Over 300 graduate students are currently
studying on the campus, and up to 2011 541 PhD and 538 MS students have
graduated. Furthermore, the IMM’s Pharmaceutical Science discipline was
named to be the “National University Medical Key Discipline” by the
Ministry of Education, with post-doctoral fellow training
certification.
IMM has the capacity to operate the institute with the market-driven
economy, which accelerates the commercialization of the basic research,
and increases the market value of the business entities that are owned
by or are affiliated to the Institute. Currently the main products
discovered and developed by IMM researchers include Bicyclol Tablets,
Paclitaxel Injection, Felodipine Tablets, Bifendate Pilules and
Polysaccharidum of G. Lucidum Karst Injection, some of which have been
launched into international markets in Europe, Asia and North Africa.
IMM has established extensive partnerships and collaboration with
pharmaceutical companies, universities and research institutes in more
than 30 countries, including Japan, the United States, Germany and
France. IMM also hosts the editorial offices of four scientific
journals: Acta Pharmaceutica Sinica, Chinese Chemical Letters,
Journal of Asian Natural Products Research and Acta
Pharmaceutica Sinica B.
In the future, IMM will work hard in the spirit of
"Devotion, Innovation, Reality and Cooperation" to launch more quality
drugs, and to make contribution for human health.
|
